期刊文献+

抗不同细胞核成分抗体与SLE病情活动不相关 被引量:4

Levels of Various Anti-nuclear Component Antibodies in Patients with SLE are not Correlated with the Disease Activity
原文传递
导出
摘要 目的探讨系统性红斑狼疮(SLE)患者ANA、抗ds-DNA抗体及其他抗细胞核成分抗体水平与SLE病情的相关性.方法选取2000-2002年我院皮肤与风湿科、肾内科住院及门诊就诊的SLE患者225例进行回顾性研究.用SLE疾病活动性指数(SLEDAI)进行病情活动性评分,按SLEDAI评分将患者分为轻度活动组(≤4分)、中度活动组(5~9分)及重度活动组(≥10分)3组.并对其中52例患者进行追踪观察.结果①225例患者抗dsDNA抗体水平和ANA滴度与SLEDAI无相关性(r1=0.054、P1=0.662,r2=0.089、P2=0.183).②抗ds-DNA抗体水平在轻度活动组与中度活动组之间差异无显著性(P>0.05),重度活动组明显高于轻度活动组与中度活动组(P<0.01).ANA滴度在3组之间差异均无显著性.抗Sm抗体、抗RNP抗体、抗SSA、SSB抗体的阳性率在3组之间差异均无显著性(P>0.05).③根据抗ds-DNA抗体结合率将患者分为<20%(第1组)、≥20%(第2组)两组,两组SLE脑病、肺部病变、浆膜炎、血管炎、关节炎、血象异常的发生率差异无显著性(P>0.05),第2组肾脏损害的发生率高于第1组(P<0.05),但这些有肾脏损害的患者蛋白尿、肌酐水平与抗ds-DNA均无相关性(P>0.05).④追踪观察52例中30例高度活动组患者抗ds-DNA抗体水平在治疗前高于治疗后(P<0.05),而22例轻、中度活动组抗ds-DNA水平在治疗前后差异无显著性(P>0.05).结论在重度活动组,抗ds-DNA抗体水平与SLE疾病活动有一定相关性;在稳定期,与疾病无相关性.ANA等其他自身抗体与SLE疾病活动无相关性.虽然抗ds-DNA抗体结合率≥20%的患者易伴有肾损害,但与严重程度无相关性. Objective To investigate the correlation between the disease activity and the serum levels of anti-nuclear autoantibodies against various nuclear components in the patients with systemic lupus erythematosus (SLE). Methods Two hundred and twenty five SLE patients enrolled from 2000 to 2002 were evaluated retrospectively. All patients fulfilled the ACR 1997 diagnostic criteria for SLE. The patients were divided into three groups according to the disease activity: mild group (Group A), moderate group (Group B)and severe group (Group C), as assessed with SLEDAI score. These cases were also divided into 2 groups according to the serum levels of anti-dsDNA antibody. 52 out of 225 patients were followed up further. Results ①There was no correlation between the serum level of anti-dsDNA antibody and SLEDAI score, and between the serum level of ANA and SLEDAI score in 225 patients. ②The serum level of anti-dsDNA antibody in group C was higher than that in group A or group B (P < 0.01), and without significant difference between group A and group B. And, there were no significant differences between the three groups both in the serum levels of ANA and in the positive rates of ENA antibodies (anti-Sm?anti-SSA/SSB?anti- RNP antibody). ③225 patients were divided into two groups according to the serum level of anti-dsDNA antibody: < 20% (Group 1), ≥20% (Group 2). The occurrence of renal damage in group 2 was higher than that in group 1 (P < 0.05). However, there was no significant difference between these two groups in the level of proteinuria or serum creatinine. ④In the fifty-two patients followed up, 30 patients with severe disease activity, the serum level of anti-dsDNA antibody decreased after treatment (P < 0.05), but no difference was shown in other 22 patients with mild to moderate disease activity (P > 0.05). Conclusions A positive correlation between the anti-dsDNA antibody and the disease activity was found in the severe group of SLE, but not found in the mild or moderate group. Although the renal damage was more commonly seen in those with higher level of anti-dsDNA antibody, but there is no correlation between the level of anti-dsDNA antibody and the degree of renal lesion.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2004年第9期509-511,共3页 Chinese Journal of Dermatology
关键词 患者 SLE 抗DS-DNA抗体 ANA 中度 相关性 轻度 显著性 Lupus erythematosus, systemic Antibodies, antinuclear
  • 相关文献

参考文献7

  • 1Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35: 630-640.
  • 2满孝勇,李学平,冒长峙,周晓鸿,谢红.系统性红斑狼疮疾病活动指数与治疗的关系探讨[J].中华皮肤科杂志,2002,35(1):17-19. 被引量:17
  • 3No authors listed. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.Arthritis Rheum, 1999, 42: 1785-1796.
  • 4Villalta D, Romelli PB, Savina C, et al. Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus, 2003, 12: 31-36.
  • 5Schiffer LE, Hussain N, Wang X, et al. Lowering anti-dsDNA antibodies--what′s new? Lupus, 2002,11: 885-894.
  • 6谢红付,李吉,陈翔,施为,陈明亮,杜乾君.系统性红斑狼疮疾病活动性与ANA及dsDNA抗体水平相关性探讨[J].中华皮肤科杂志,2003,36(7):404-404. 被引量:3
  • 7Yee CS, Hussein H, Skan J, et al. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford), 2003, 42: 276-279.

二级参考文献6

共引文献18

同被引文献39

  • 1舒强,刘静,刘花香,李兴福.系统性红斑狼疮患者151例的生存质量及其影响因素[J].中华风湿病学杂志,2004,8(7):420-423. 被引量:25
  • 2李久宏,李萍,韩世新,耿龙,宋芳吉.女性系统性红斑狼疮患者血清瘦素水平的检测及意义[J].中国麻风皮肤病杂志,2004,20(6):511-512. 被引量:9
  • 3仲人前,耿红莲.自身免疫性疾病实验室诊断进展[J].中华检验医学杂志,2005,28(8):867-869. 被引量:32
  • 4李永哲.自身抗体检测技术临床推广应用和质量保证工作中应重视的问题[J].中华检验医学杂志,2006,29(9):769-773. 被引量:81
  • 5Primavera A, Audenino D, Mavilio N, et al. Reversible posterior leucoencephalopathy syndrome in systemic lupus and vasculitis[J].Ann Rheum Dis, 2001, 60(5): 534-537.
  • 6郑捷 许以平 郑捷.结缔组织疾病[A].许以平,郑捷.现代免疫学检验与临床实践[M].上海:上海科技文献出版社,1999.61-101.
  • 7Futei Y, Amagai M, Ishii K, et al. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus[J]. J Dermatol Sci, 2001, 26(1): 55-61.
  • 8Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects[J]. Proc Natl Acad Sci U S A, 2004, 101(1): 227-232.
  • 9Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology[J]. Ann Rheum Dis, 2002, 61(8): 718-722.
  • 10Galon J, Franchimont D, Hiroi N, et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells[J]. FASEB J, 2002. 16(1): 61-71.

引证文献4

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部